Skip to main content
Premium Trial:

Request an Annual Quote

Agilent Buys Nucleic Acid Medicines Business from Dowpharma

NEW YORK (GenomeWeb News) – Agilent Technologies announced today that it has acquired the nucleic acid medicines business of Dowpharma for an undisclosed sum.
 
The acquisition is concurrent with an expansion of its nucleic acid active pharmaceutical ingredient manufacturing facility in Boulder, Colo. Agilent said that it would add large-scale nucleic acid synthesis, purification, and drying capacity to its capabilities by the end of this year.
 
“Agilent will have the ability to serve customers from pre-clinical through large-scale commercial launch with facilities, equipment, and expertise across a broad range of nucleic acid APIs,” James Powell, general manager of Agilent’s Nucleic Acid Solutions Division, said in a statement.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.